Henry Schein beats Q3 profit estimates and raises FY2026 guidance
Henry Schein reported third-quarter 2026 results for the period ended September 26, with total sales of $3.5 billion, up 4.0%, and non-GAAP diluted EPS of $1.56, up 13.0% year over year. GAAP diluted EPS was $1.06, up 26.2%, while U.S. dental merchandise sales increased 8.6%. The company raised FY2026 non-GAAP diluted EPS guidance to $5.50 to $5.56 and lifted its adjusted EBITDA growth outlook to high-single-digits.
Why it matters
The higher earnings outlook increases Henry Schein's stated profit expectations for FY2026, while the quarter's sales growth and dental merchandise performance provide the operating basis for the revision. The guidance includes a net tariff refund benefit and targeted growth investments, and the company assumes no significant additional tariff refunds or remeasurement gains for the rest of 2026.
Key facts
- 1Henry Schein reported third-quarter 2026 GAAP diluted EPS of $1.06, up 26.2% from the prior year. sec.gov
- 2Third-quarter 2026 non-GAAP diluted EPS was $1.56, up 13.0% year over year. sec.gov
- 3Total third-quarter sales were $3.5 billion, with 4.0% total growth and 3.1% internal growth in local currencies. sec.gov
- 4U.S. dental merchandise sales grew 8.6%, primarily from volume and market-share gains. sec.gov
- 5Henry Schein raised FY2026 non-GAAP diluted EPS guidance to $5.50 to $5.56 and forecast adjusted EBITDA growth in the high-single-digits. sec.gov
- 6The company recorded a $0.19 per diluted share net benefit from tariff refunds in the quarter. sec.gov
Open questions
- Material 8 reports FY2026 adjusted EPS guidance of $5.53, which differs from the $5.50 to $5.56 range reported in the company filing.
- Material 14 additionally reports a 2026 sales-growth outlook of 4.5%-5.5%, but the primary filing excerpt does not show the updated sales-growth guidance table.
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.